Co-Diagnostics Inc
CODX
Company Profile
Business description
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Contact
2401 S. Foothill Drive
Suite D
Salt Lake CityUT84109
USAT: +1 801 438-1036
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
115
Stocks News & Analysis
stocks
Guzman Y Gomez’s outlook unchanged despite strong update
Strong quarter yet shares remain expensive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.40 | 28.60 | -0.32% |
| CAC 40 | 7,894.90 | 21.79 | 0.28% |
| DAX 40 | 25,248.34 | 50.27 | -0.20% |
| Dow JONES (US) | 51,888.87 | 267.39 | 0.52% |
| FTSE 100 | 10,819.57 | 94.71 | 0.88% |
| HKSE | 24,062.72 | 251.45 | -1.03% |
| NASDAQ | 26,480.39 | 212.47 | -0.80% |
| Nikkei 225 | 64,425.95 | 3,318.34 | -4.90% |
| NZX 50 Index | 13,832.80 | 72.41 | 0.53% |
| S&P 500 | 7,702.41 | 16.53 | -0.21% |
| S&P/ASX 200 | 8,719.70 | 8.20 | -0.09% |
| SSE Composite Index | 3,707.48 | 59.75 | -1.59% |